Drugs / ST002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06834438 | Feb 2025 → Feb 2026 overdue | NF2-related schwannomatosis | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06834438 ↗ |
| Action | Restore | “By reinserting the normal XXX gene into genetically deficient tumor cells, the product expresses Merlin.” NCT06834438 ↗ |
| Route | Other | “intra-tumoral injection” NCT06834438 ↗ |
| Target | NF2 | “a lentiviral vector designed to drive expression of the NF2 protein product, Merlin.” NCT06834438 ↗ |